4-[4-[2-[[3-(2-aminoethyl)-1H-indol-5-yl]oxy]acetyl]piperazin-1-yl]benzonitrile hydrochloride
| Title | Journal |
|---|---|
| Donitriptan, but not sumatriptan, inhibits capsaicin-induced canine external carotid vasodilatation via 5-HT1B rather than 5-HT1D receptors. | British journal of pharmacology 20060901 |
| Donitriptan decreases jugular venous oxygen saturation in rats in the absence of cranial vasoconstriction: an overlooked mechanism of antimigraine action? | The Journal of pharmacology and experimental therapeutics 20051101 |
| Donitriptan selectively decreases jugular venous oxygen saturation in the anesthetized pig: further insights into its mechanism of action relevant to headache relief. | The Journal of pharmacology and experimental therapeutics 20030501 |
| Therapies in development for the treatment of migraine. | Expert opinion on investigational drugs 20021201 |
| Comparison of contractile responses to donitriptan and sumatriptan in the human middle meningeal and coronary arteries. | European journal of pharmacology 20020517 |
| Effects of donitriptan on carotid haemodynamics and cardiac output distribution in anaesthetized pigs. | Cephalalgia : an international journal of headache 20020201 |
| An in vivo rat model to study calcitonin gene related peptide release following activation of the trigeminal vascular system. | Pain 20010501 |
| Donitriptan (Pierre Fabre). | Current opinion in investigational drugs (London, England : 2000) 20010301 |
| F 11356, a novel 5-hydroxytryptamine (5-HT) derivative with potent, selective, and unique high intrinsic activity at 5-HT1B/1D receptors in models relevant to migraine. | The Journal of pharmacology and experimental therapeutics 19990701 |